Coronavirus: Commission approves second contract with Moderna to ensure up to additional 300 million doses
The European Commission yesterday approved a second contract with the pharmaceutical company Moderna, which provides for an additional purchase of 300 million doses (150 million in 2021 and an option to purchase an additional 150 million in 2022) on behalf of all EU Member States. The new contract also provides for the possibility to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Yesterday's contract with Moderna builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed contracts with BioNTech/Pfizer, AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, Curevac and Moderna. This diversified vaccines portfolio will ensure Europe has access to 2.6 billion doses, once the vaccines have been proven to be safe and effective.
President of the European Commission, Ursula von der Leyen, yesterday said:
“Today, we are securing 300 million additional doses of the COVID-19 vaccine produced by Moderna, which is already used for vaccination in the European Union. This brings us closer to our major objective: ensure that all Europeans have access to safe and effective vaccines as quickly as possible. With a portfolio of up to 2.6 billion doses, we will be able to provide vaccines not just to our citizens, but to our neighbours and partners as well.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“With this new contract with Moderna, we are adding another 300 million doses of an authorised safe and effective vaccine. It marks another step towards our objective of providing swift access to safe and effective vaccinations to citizens in Europe and beyond over the course of this year. The contract is important not only for the short term needs of the EU, but also for our future work to limit the rapid spread of new variants.”
The Moderna vaccine is based on messenger RNA (mRNA). mRNA plays a fundamental role in biology, transferring instructions from DNA to the cells' protein making machinery. In an mRNA vaccine, these instructions produce harmless fragments of the virus, which the human body uses to build an immune response to prevent or fight disease. When a person is given the vaccine, their cells will read the genetic instructions and produce a spike protein, a protein on the outer surface of the virus which it uses to enter the body's cells and cause disease. The person's immune system will then treat this protein as foreign and produce natural defences – antibodies and T cells – against it.
The Commission has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the companies' experience in vaccine development and their production capacity to supply the whole of the EU, as well as their capacity to potentially develop a vaccine against coronavirus variants.
Latest News from
NextGenerationEU: European Commission disburses €271 million in pre-financing to Finland21/01/2022 15:25:00
The European Commission has today disbursed €271 million to Finland in pre-financing, equivalent to 13% of the country's financial allocation under the Recovery and Resilience Facility (RRF).
EU challenges Russian export restrictions on wood at WTO21/01/2022 13:25:00
Today, the EU is requesting consultations with Russia at the World Trade Organization (WTO) concerning export restrictions placed by Russia on wood products.
‘State of the World' Special Address by President von der Leyen at the World Economic Forum, via videoconference21/01/2022 11:33:00
‘State of the World' Special Address given yesterday by President von der Leyen at the World Economic Forum, via videoconference.
Protecting consumers from misleading reviews: 55% of screened websites violate EU law21/01/2022 10:38:00
The European Commission and national consumer protection authorities yesterday released the results of an EU-wide website screening (“sweep”) on online consumer reviews.
Speech by President von der Leyen at the European Women on Boards' Gender Diversity Award21/01/2022 09:25:00
Speech given yesterday by President von der Leyen at the European Women on Boards' Gender Diversity Award.
Speech by Executive Vice-President Vestager on the Digital Services Act20/01/2022 16:33:00
Speech given yesterday by Executive Vice-President Vestager on the Digital Services Act.
European Globalisation Adjustment Fund: €2.8 million to support dismissed workers in the Spanish car industry20/01/2022 15:25:00
Today, the European Commission proposes to support 450 workers who lost their jobs in the car industry in the Spanish region of Catalonia with €2.8 million from the European Globalisation Adjustment Fund for Displaced Workers (EGF).
Intellectual property: Statement by EU Internal Market Commissioner Thierry Breton welcoming the provisional application of the Unitary Patent20/01/2022 14:33:00
Intellectual property: Statement given yesterday by EU Internal Market Commissioner Thierry Breton welcoming the provisional application of the Unitary Patent.
Speech by Commissioner Breton on the Digital Services Act20/01/2022 13:25:00
Speech given yesterday by Commissioner Breton on the Digital Services Act.
EU Cohesion policy: Almost €385.5 million from the EU Solidarity Fund to 19 countries to tackle the coronavirus health emergency20/01/2022 12:38:00
The Commission completed the payments of the EU Solidarity Fund (EUSF) assistance to tackle the coronavirus health emergency to 19 countries for a total amount of almost €385.5 million.